CardioMEMS
Industry: MEMS medical devices
CardioMEMS developed the first and only FDA-approved heart failure monitor proven to significantly reduce heart failure hospital admissions and improve quality of life in NYHA class III patients.
The CardioMEMS™ HF System – which features a miniaturized wireless sensor that can be implanted through a catheter, without need for surgery – has been shown to reduce heart failure admissions by 37% and readmissions by 78%.
The device uses wireless communications technology to transmit data on cardiac output, blood pressure and heart rate to the patient’s doctor, who can then monitor the patient’s health from afar as well as suggest more personally tailored treatment plans.
Note: St. Jude Medical acquired CardioMEMS in 2014 for more than $450 million and has put the system to work for heart patient health. The technology is now part of Abbott >
